BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1771411)

  • 1. Neutralization of recombinant hirudin: some practical considerations.
    Fareed J; Walenga JM; Hoppensteadt D; Iyer L; Pifarre R
    Semin Thromb Hemost; 1991 Apr; 17(2):137-44. PubMed ID: 1771411
    [No Abstract]   [Full Text] [Related]  

  • 2. Anticoagulant and antithrombotic actions of recombinant hirudin.
    Kaiser B
    Semin Thromb Hemost; 1991 Apr; 17(2):130-6. PubMed ID: 1837615
    [No Abstract]   [Full Text] [Related]  

  • 3. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin.
    Fareed J; Walenga JM; Pifarre R; Hoppensteadt D; Koza M
    Haemostasis; 1991; 21 Suppl 1():64-72. PubMed ID: 1894198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comeback of hirudin as an antithrombotic agent.
    Markwardt F
    Semin Thromb Hemost; 1991 Apr; 17(2):79-82. PubMed ID: 1771415
    [No Abstract]   [Full Text] [Related]  

  • 5. The direct thrombin inhibitor hirudin.
    Greinacher A; Warkentin TE
    Thromb Haemost; 2008 May; 99(5):819-29. PubMed ID: 18449411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of barbourin--albumin and hirudin--albumin fusion proteins limits fibrin(ogen) deposition on the rabbit balloon-injured aorta.
    Sheffield WP; Gataiance S; Eltringham-Smith LJ
    Thromb Res; 2007; 119(2):195-207. PubMed ID: 16478628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations.
    Walenga JM; Pifarre R; Hoppensteadt DA; Fareed J
    Semin Thromb Hemost; 1989 Jul; 15(3):316-33. PubMed ID: 2688104
    [No Abstract]   [Full Text] [Related]  

  • 11. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
    Agnelli G; Pascucci C; Cosmi B; Nenci GG
    Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
    Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
    Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
    Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
    Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombin effects of native and recombinant hirudins.
    Markwardt F; Stürzebecher J; Glusa E
    Biomed Biochim Acta; 1990; 49(5):399-404. PubMed ID: 2271010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hirudin versus heparin and low-molecular-weight heparin: and the winner is..
    Hull RD; Pineo GF; Raskob GE
    J Lab Clin Med; 1998 Sep; 132(3):171-4. PubMed ID: 9735921
    [No Abstract]   [Full Text] [Related]  

  • 16. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat.
    Butler KD; Dolan SL; Talbot MD; Wallis RB
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):459-64. PubMed ID: 8329573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
    Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
    Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of heparin and hirudin on thrombin generation and platelet aggregation after intrinsic activation of platelet rich plasma.
    Gallistl S; Muntean W; Leis HJ
    Thromb Haemost; 1995 Oct; 74(4):1163-8. PubMed ID: 8560429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Dec; (8):225-35. PubMed ID: 12603879
    [No Abstract]   [Full Text] [Related]  

  • 20. Unstable angina.
    Natarajan M
    Clin Evid; 2002 Jun; (7):214-26. PubMed ID: 12230645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.